. 2020 Jul 14;76(12):1659–1665. doi: 10.1007/s00228-020-02960-7

Table 3.

Summary of simulation results of PBPK modeling for effect of lusutrombopag with multiple dose of 3 mg or 6 mg on pharmacokinetics of midazolam

Lusutrombopag dose	Parameter	Geometric mean (90% PI)		Ratio (with/alone)^a
Lusutrombopag dose	Parameter	Alone	With	Ratio (with/alone)^a
3 mg	C_max (ng/mL)	15.61 (6.36, 39.29)	16.57 (6.87, 40.58)	1.05 (1.02, 1.12)
3 mg	AUC (ng h/mL)	56.20 (16.46, 139.10)	59.67 (17.78, 143.50)	1.05 (1.02, 1.12)
6 mg^b	C_max (ng/mL)	15.61 (6.36, 39.29)	17.32 (7.36, 41.55)	1.10 (1.04, 1.23)
6 mg^b	AUC (ng h/mL)	56.20 (16.46, 139.10)	62.38 (19.01, 146.77)	1.10 (1.04, 1.23)

PI, prediction interval

^aMedian (90% PI)

^bThe 6-mg dose was tested to achieve comparable exposure at the clinical dose of 3 mg once daily for 7 days in the target patients